Taysha Gene Therapies, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -42.98M-174.52M-166.00M-73.86M-84.62M
Depreciation and Depletion 0.01M0.50M1.20M1.40M1.25M
Share-based Compensation 3.35M18.18M18.04M7.91M13.10M
Gains from Sales and Divestitures 0.63M0.56M0.32M
Gains from Investment Securities 26.25M1.07M7.16M3.70M
Asset Writedowns and Impairment 36.42M1.06M4.84M
Non-cash Items 0.06M1.96M15.50M
Cash from Operations -30.73M-117.04M-88.39M-73.02M-81.22M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.31M1.18M1.22M
Depreciation & Amortization (CF) 0.01M0.50M1.20M1.40M1.25M
Change in Working Capital
Change in Account Payables 1.96M14.49M-7.80M-2.29M-2.92M
Change in Accured Expenses 4.51M17.54M-9.32M-6.28M-1.42M
Investing Activities
Capital Expenditures 0.08M15.30M20.62M3.87M0.37M
Cash from Investing Activities -9.08M-21.55M-24.93M-7.35M-0.36M
Financing Activities
Other financing activities -0.51M-1.04M0.40M-0.17M
Debt Issuance and Repayment
Long-Term Debt Issuances 1.67M
Change in Capital Stock
Shares Issued 165.85M0.25M0.50M0.09M
Preferred Shares Issued 95.81M
Misc.
Cash from Financing Activities 291.06M39.08M52.10M136.39M76.68M
Change in Cash 251.25M-99.51M-61.22M56.02M-4.90M
Beginning Cash Balance 1.67M
Free Cash Flow -30.81M-132.35M-109.01M-76.89M-81.60M
Net Cash Flow 251.25M-99.51M-61.22M56.02M-4.90M